Literature DB >> 21921261

N-terminal pro-brain natriuretic peptide and risk of cardiovascular events in a Japanese community: the Hisayama study.

Yasufumi Doi1, Toshiharu Ninomiya, Jun Hata, Yoichiro Hirakawa, Naoko Mukai, Fumie Ikeda, Masayo Fukuhara, Masanori Iwase, Yutaka Kiyohara.   

Abstract

OBJECTIVE: Few studies have examined the association between natriuretic peptides and the incidence of cardiovascular disease (CVD) in Asian populations. METHODS AND
RESULTS: A total of 3104 community-dwelling Japanese individuals aged ≥40 years without history of CVD were followed up for 5 years. A total of 127 CVD events were identified. The age- and sex-adjusted incidence of CVD increased with increasing N-terminal pro-brain natriuretic peptide (NT-proBNP) levels (<55, 55-124, 125-399, and ≥400 pg/mL) at baseline and was significantly higher even in subjects with a modest increase. This association remained robust even after adjustment for other potential risk factors (55-124 pg/mL: multivariate-adjusted hazard ratio=1.85 [95% CI 1.07-3.18], P=0.03; 125-399 pg/mL: 2.98 [95% CI 1.65-5.39], P<0.001; ≥400 pg/mL: 4.54 [95% CI 2.22-9.29], P<0.001). The multivariate-adjusted hazard ratios for the development of total CVD and its subtypes, coronary heart disease and stroke, were significantly increased by a 1 SD increment of the log NT-proBNP concentrations and were nearly equal among CVD subtypes. Similar findings were observed for stroke subtypes of ischemic stroke and intracerebral hemorrhage but not subarachnoid hemorrhage. The effects of the 1 SD increment in log NT-proBNP values were comparable in subjects with and without other cardiovascular risk factors, except for sex. The area under the receiver operating characteristic curve was significantly (P=0.006) increased by adding NT-proBNP values to the model including other potential risk factors.
CONCLUSIONS: Elevated NT-proBNP levels were shown to be a significant risk factor for the development of CVD and its subtypes in a general Japanese population, independently of other cardiovascular risk factors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21921261     DOI: 10.1161/ATVBAHA.111.223669

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  16 in total

Review 1.  Clinical utility of novel biomarkers for cardiovascular disease risk stratification.

Authors:  Maurizio Averna; Davide Noto
Journal:  Intern Emerg Med       Date:  2012-10       Impact factor: 3.397

2.  Expanding the role of cardiac biomarkers--natriuretic peptides and troponins--further in pre-Stage A.

Authors:  Yoshihiko Seino; Toshiaki Otsuka
Journal:  Hypertens Res       Date:  2014-09-25       Impact factor: 3.872

3.  Plasma B-type natriuretic peptide is a useful tool for assessing coronary heart disease risk in a Japanese general population.

Authors:  Takuya Hasegawa; Masanori Asakura; Kazuo Eguchi; Hiroshi Asanuma; Takahiro Ohara; Hideaki Kanzaki; Kazuhiko Hashimura; Hitonobu Tomoike; Jiyoong Kim; Masafumi Kitakaze
Journal:  Hypertens Res       Date:  2014-08-14       Impact factor: 3.872

4.  Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality.

Authors:  Oludamilola W Oluleye; Aaron R Folsom; Vijay Nambi; Pamela L Lutsey; Christie M Ballantyne
Journal:  Ann Epidemiol       Date:  2012-12-08       Impact factor: 3.797

5.  Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the atherosclerosis risk in communities study.

Authors:  Aaron R Folsom; Vijay Nambi; Elizabeth J Bell; Oludamilola W Oluleye; Rebecca F Gottesman; Pamela L Lutsey; Rachel R Huxley; Christie M Ballantyne
Journal:  Stroke       Date:  2013-03-07       Impact factor: 7.914

6.  Serial measurement of N-terminal pro-B-type natriuretic peptide and cardiac troponin T for cardiovascular disease risk assessment in the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Lori B Daniels; Paul Clopton; Christopher R deFilippi; Otto A Sanchez; Hossein Bahrami; Joao A C Lima; Russell P Tracy; David Siscovick; Alain G Bertoni; Philip Greenland; Mary Cushman; Alan S Maisel; Michael H Criqui
Journal:  Am Heart J       Date:  2015-09-28       Impact factor: 4.749

7.  N-terminal fragment of probrain natriuretic peptide is associated with diabetes microvascular complications in type 2 diabetes.

Authors:  Kumiko Hamano; Ikue Nakadaira; Jun Suzuki; Megumi Gonai
Journal:  Vasc Health Risk Manag       Date:  2014-10-03

8.  N-terminal pro-brain natriuretic peptide and cardiovascular or all-cause mortality in the general population: A meta-analysis.

Authors:  Zhaohua Geng; Lan Huang; Mingbao Song; Yaoming Song
Journal:  Sci Rep       Date:  2017-01-30       Impact factor: 4.379

9.  Association of serum carotenoid levels with N-terminal pro-brain-type natriuretic peptide: a cross-sectional study in Japan.

Authors:  Koji Suzuki; Junichi Ishii; Fumihiko Kitagawa; Atsuhiro Kuno; Yasuhiro Kusuhara; Junichi Ochiai; Naohiro Ichino; Keisuke Osakabe; Keiko Sugimoto; Hiroya Yamada; Yoshinori Ito; Nobuyuki Hamajima; Takashi Inoue
Journal:  J Epidemiol       Date:  2013-03-09       Impact factor: 3.211

10.  Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis.

Authors:  Peter Willeit; Stephen Kaptoge; Paul Welsh; Adam Butterworth; Rajiv Chowdhury; Sarah Spackman; Lisa Pennells; Pei Gao; Stephen Burgess; Daniel Freitag; Michael Sweeting; Angela Wood; Nancy Cook; Suzanne Judd; Stella Trompet; Vijay Nambi; Michael Olsen; Brendan Everett; Frank Kee; Johan Ärnlöv; Veikko Salomaa; Daniel Levy; Jussi Kauhanen; Jari Laukkanen; Maryam Kavousi; Toshiharu Ninomiya; Juan-Pablo Casas; Lori Daniels; Lars Lind; Caroline Kistorp; Jens Rosenberg; Thomas Mueller; Speranza Rubattu; Demosthenes Panagiotakos; Oscar Franco; James de Lemos; Andreas Luchner; Jorge Kizer; Stefan Kiechl; Jukka Salonen; S Goya Wannamethee; Rudolf de Boer; Børge Nordestgaard; Jonas Andersson; Torben Jørgensen; Olle Melander; Christie Ballantyne; Christopher DeFilippi; Paul Ridker; Mary Cushman; Wayne Rosamond; Simon Thompson; Vilmundur Gudnason; Naveed Sattar; John Danesh; Emanuele Di Angelantonio
Journal:  Lancet Diabetes Endocrinol       Date:  2016-09-03       Impact factor: 44.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.